SPRAVATO Treatment at Valor Health

Now Offering SPRAVATO Treatment

For Adults with Treatment-Resistant Depression

A new FDA-approved nasal spray treatment, available at Valor Health for adults struggling with depression that hasn’t responded to traditional medication.

Book a Consultation

What Is SPRAVATO?

(esketamine) CIII nasal spray is an FDA-approved medication used in combination with an oral antidepressant to treat:

Adults with treatment-resistant depression (TRD)
Adults with major depressive disorder (MDD) experiencing suicidal thoughts or behavior
Patients who have tried two or more antidepressants without relief
Patients who may benefit from a fast-acting treatment option under medical supervision

SPRAVATO Patient Brochure (PDF)

How the Treatment Works

A Different Approach to Depression Treatment

SPRAVATO may offer an alternate path for those who have tried two or more antidepressants without success.

It is administered in-office and initially taken twice a week, then tapering to once a week or every other week.

Is SPRAVATO Right for You?

SPRAVATO might be a good fit if:

You’ve been diagnosed with treatment-resistant depression (TRD)
You’ve tried at least two other antidepressants without sufficient relief
You’re under the care of a healthcare provider who can coordinate your treatment
You’re looking for a monitored treatment administered in a clinical setting

Request a Screening Call

Important Safety Information

SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness as an anesthetic have not been established.

Please note: SPRAVATO is only available through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered in a certified medical facility under supervision.

More Safety Information